“Adapt or become irrelevant” is the stark message that Janssen’s Company Group Chairman for Europe, Middle East and Africa (EMEA), Kris Sterkens, has for pharma companies that fail to embrace t
Cancer Research UK has provided £5.9 million ($7.7 million) in funding to a project that will explore the use of artificial intelligence in trials of radiotherapy treatments as well as virt
